» Articles » PMID: 28554238

Greater Sensitivity to Multiple Sclerosis Disability Worsening and Progression Events Using a Roving Versus a Fixed Reference Value in a Prospective Cohort Study

Overview
Journal Mult Scler
Publisher Sage Publications
Specialty Neurology
Date 2017 May 31
PMID 28554238
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Confirmed Expanded Disability Status Scale (EDSS) progression occurring after a fixed-study entry baseline is a common measure of disability increase in relapsing-remitting multiple sclerosis (RRMS) studies but may not detect all disability progression events, especially those unrelated to overt relapses.

Objective: To evaluate possible measures of disability progression unrelated to relapse using EDSS data over ≈5.5 years from the Tysabri Observational Program (TOP).

Methods: TOP is an ongoing, prospective, open-label study in RRMS patients receiving intravenous 300 mg natalizumab every 4 weeks. Measures of increasing disability were assessed using as a reference either study baseline score or a "roving" system that resets the reference score after ⩾24- or ⩾48-week confirmation of a new score.

Results: This analysis included 5562 patients. Approximately 70% more EDSS progression events unrelated to relapse and 50% more EDSS worsening events overall were detected with a roving reference score (cumulative probability: 17.6% and 29.7%, respectively) than with a fixed reference baseline score (cumulative probability: 10.1% and 20.3%, respectively).

Conclusion: In this long-term observational RRMS dataset, a roving EDSS reference value was more efficient than a study baseline EDSS reference in detecting progression/worsening events unrelated to relapses and thus the transition to secondary progressive disease.

Citing Articles

Paramagnetic rim lesions are associated with inner retinal layer thinning and progression independent of relapse activity in multiple sclerosis.

Krajnc N, Hofer L, Fottinger F, Dal-Bianco A, Leutmezer F, Kornek B Eur J Neurol. 2024; 32(1):e16529.

PMID: 39529542 PMC: 11622274. DOI: 10.1111/ene.16529.


Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.

Reeves J, Bartnik A, Jakimovski D, Mohebbi M, Bergsland N, Salman F Neurology. 2024; 103(10):e210004.

PMID: 39447104 PMC: 11509899. DOI: 10.1212/WNL.0000000000210004.


Multiple sclerosis: emerging epidemiological trends and redefining the clinical course.

Portaccio E, Magyari M, Kubala Havrdova E, Ruet A, Brochet B, Scalfari A Lancet Reg Health Eur. 2024; 44:100977.

PMID: 39444703 PMC: 11496978. DOI: 10.1016/j.lanepe.2024.100977.


Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.

Simone M, Lucisano G, Guerra T, Paolicelli D, Rocca M, Morra V J Neurol. 2024; 271(10):6782-6790.

PMID: 39179712 PMC: 11447039. DOI: 10.1007/s00415-024-12638-0.


Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.

Ciccarelli O, Barkhof F, Calabrese M, De Stefano N, Eshaghi A, Filippi M Neurology. 2024; 103(1):e209444.

PMID: 38889384 PMC: 11226318. DOI: 10.1212/WNL.0000000000209444.


References
1.
Kalincik T, Cutter G, Spelman T, Jokubaitis V, Havrdova E, Horakova D . Defining reliable disability outcomes in multiple sclerosis. Brain. 2015; 138(Pt 11):3287-98. DOI: 10.1093/brain/awv258. View

2.
Koch M, Mostert J, Heersema D, De Keyser J . Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. 2007; 255(1-2):35-41. DOI: 10.1016/j.jns.2007.01.067. View

3.
Bosma L, Kragt J, Polman C, Uitdehaag B . Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Mult Scler. 2012; 19(3):326-33. DOI: 10.1177/1352458512454346. View

4.
Lublin F, Reingold S . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4):907-11. DOI: 10.1212/wnl.46.4.907. View

5.
Bosma L, Sonder J, Kragt J, Polman C, Uitdehaag B . Detecting clinically-relevant changes in progressive multiple sclerosis. Mult Scler. 2014; 21(2):171-9. DOI: 10.1177/1352458514540969. View